Pulmotect

Focus: Pulmotect is a pre-revenue biotechnology company focused on inhalable small-molecule therapeutics for infectious diseases and respiratory conditions, headquartered in Houston, TX.

Infectious Diseases Respiratory

Profile data last refreshed 2d ago · AI intelligence enriched 2w ago

Open Jobs

About Pulmotect

AI assessmentNot Hiring

No open roles listed right now. Follow Pulmotect to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

7 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

PUL-042 Inhalation Solution

Healthy

Phase 1

Clinical Trials (1)

NCT02566252Effect of Pre-Treatment With Cromolyn or Albuterol on Response to PUL-042 Inhalation Solution (PUL-042)

Phase 1

Help build intelligence for Pulmotect

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Early-stage platform company with novel inhalation technology addressing high-unmet-need respiratory and infectious disease markets
Diversified pipeline across COVID-19, COPD, and hematologic indications suggests multiple shots on goal
Houston location offers lower cost of living compared to biotech hubs while building a novel therapeutic platform

Watch Out For

No marketed products or revenue; company stage and funding status unknown, creating significant cash-runway uncertainty
Early pipeline (3 Phase 1, 4 Phase 2 programs) with no Phase 3 data or near-term regulatory catalysts visible
Zero current open positions and no disclosed funding or employee count suggest very early or restructured operations

Generated by Claude from Pulmotect's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

PUL-042 Inhalation Solution

Healthy

Phase 1

Clinical Trials (1)

NCT02124278Safety and Tolerability of Single Ascending Doses of PUL-042 Inhalation Solution in Healthy Subjects

Phase 1

PUL-042

Hematologic Diseases

Phase 1

Clinical Trials (1)

NCT03097796A Multiple Ascending Dose Study of PUL-042 in Stem Cell Transplant Recipients

Phase 1